CN Patent

CN118984701A — 米达美替尼治疗

Assigned to Springworths Treatment Co ltd · Expires 2024-11-19 · 1y expired

What this patent protects

本公开涉及一种用于通过向患者口服施用有效量的米达美替尼来治疗某些类型的肿瘤或癌症，诸如丛状神经纤维瘤(PN)、与1型神经纤维瘤病相关的丛状神经纤维瘤(NF1‑PN)的方法，其中在治疗第一天施用一定量的米达美替尼以提供(i)小于400ng·h/mL的AUC 0‑tau ，(ii)不超过40ng/mL的C max ，或(iii)两者。

USPTO Abstract

本公开涉及一种用于通过向患者口服施用有效量的米达美替尼来治疗某些类型的肿瘤或癌症，诸如丛状神经纤维瘤(PN)、与1型神经纤维瘤病相关的丛状神经纤维瘤(NF1‑PN)的方法，其中在治疗第一天施用一定量的米达美替尼以提供(i)小于400ng·h/mL的AUC 0‑tau ，(ii)不超过40ng/mL的C max ，或(iii)两者。

Drugs covered by this patent

Patent Metadata

Patent number
CN118984701A
Jurisdiction
CN
Classification
—
Expires
2024-11-19
Drug substance claim
No
Drug product claim
No
Assignee
Springworths Treatment Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.